90 research outputs found
Head-to-head intra-individual comparison of [Ga-68]-FAPI and [F-18]-FDG PET/CT in patients with bladder cancer
Get PDFDATA AVAILABILITY : The data used and/or analyzed during the current study are available from the corresponding author on reasonable request.Please read abstract in the article.Open Access funding enabled and organized by Projekt DEAL.https://link.springer.com/journal/11307hj2023Nuclear Medicin
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
Get PDFHistone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
Full text linkComplications and health-related quality of life after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis of four RCTs
Full text linkRamucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Get PDFFew treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population
Second-line treatment of advanced urothelial cancer - safety of combinatory treatment with paclitaxel and RAD001 (everolimus) in a German phase II trial (AUO trial AB 35/09)
No full text
491 HDAC (HISTONE DEACETYLASE) EXPRESSION PATTERNS IN UROTHELIAL CANCER AND THEIR IMPACT ON THE ACTION OF HDAC INHIBITORS
No full textPrognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel: German Association of Urological Oncology (AUO) trial AB 20/99.
No full text
- …
